- Conditions
- Heart Failure, Left Ventricular Systolic Dysfunction
- Interventions
- Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 29 Days to 17 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more
Location Directory
Clinical trials in Cleveland, Ohio
This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
11325
Shown on this page
12
Local exact-city summaries
2318
Based on exact city/state matches in the local index.
Local exact-city recruiting
1235
Live official results below use the broader ClinicalTrials.gov location search.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 1–12 of 11,325 matching trials in Cleveland, OH.
Live ClinicalTrials.gov results.
Top conditions in local exact-city summaries
Top sponsors in local exact-city summaries
Top therapies in local exact-city summaries
Institutions in Cleveland
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- Interventions
- Adagrasib, Pembrolizumab
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 220
- States / cities
- Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more
- Conditions
- Persistent Infection, Cystic Fibrosis
- Interventions
- CMTX-101, Placebo
- Drug
- Lead sponsor
- Clarametyx Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more
- Conditions
- Immune Thrombocytopenic Purpura (ITP)
- Interventions
- Mezagitamab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 25
- States / cities
- Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 347
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more
- Conditions
- Relapsing Multiple Sclerosis, Multiple Sclerosis
- Interventions
- No Intervention
- Other
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 100 more
- Conditions
- Spinal Cord Injury (SCI), Gait
- Interventions
- NNP-LE
- Device
- Lead sponsor
- Louis Stokes VA Medical Center
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Advanced Solid Tumor, Mesothelioma, Malignant
- Interventions
- SW-682, Combination Therapy
- Drug
- Lead sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 5 more
- Conditions
- Essential Thrombocythemia
- Interventions
- INCA033989, Best Available Treatment
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 36 more
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
- Drug · Other
- Lead sponsor
- Opus Genetics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 5
- States / cities
- Mission Hills, California • Morrow, Georgia • Ann Arbor, Michigan + 2 more
- Conditions
- Intracerebral Hemorrhage, Stroke, Hypertension
- Interventions
- Clevidipine Injection, Alternate IV Antihypertensive Regimen
- Drug
- Lead sponsor
- Zeenat Qureshi Stroke Institute
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,018 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 21
- States / cities
- Irvine, California • Lancaster, California • Palo Alto, California + 17 more
- Conditions
- Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography and Computed Tomography Scan, Lumbar Puncture, Multigated Acquisition Scan, Tovorafenib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 180 Days to 22 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 85 more